Graham Capital Management, L.P. Altimmune, Inc. Transaction History

Graham Capital Management, L.P.

  • $4.42 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 22, 2023
SELL
$2.4 - $3.45 $118,377 - $170,167
-49,324 Reduced 34.39%
94,105 $244,000
Q2 2023

Aug 14, 2023
BUY
$3.45 - $5.97 $494,830 - $856,271
143,429 New
143,429 $506,000
Q2 2022

Aug 15, 2022
SELL
$3.94 - $11.77 $40,759 - $121,760
-10,345 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$5.9 - $9.45 $61,035 - $97,760
10,345 New
10,345 $63,000

Others Institutions Holding ALT

# of Institutions
186
Shares Held
39.3M
Call Options Held
913K
Put Options Held
743K
View Full List

About Altimmune, Inc.

ALT Quotes by TradingView
  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $404M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email